



सत्यमेव जयते

GOVERNMENT OF INDIA  
CENTRAL DRUGS STANDARD CONTROL  
ORGANISATION (Headquarter)  
(Directorate General of Health Services)  
Ministry of Health & Family Welfare  
Bhavan  
ITO, Kotla Road  
New Delhi - 110002 (Delhi)  
Phone No.: 91-11-23216367  
Fax No.: 91-11-23236973  
E-Mail : dci@nic.in

**File No. CT/24/000140**

To,

M/s IQVIA RDS (India) Private Limited,  
Omega Embassy TechSquare Marathahalli-Sarjapur,  
Outer Ring Road Kadubeesanahalli Bangalore (India) – 560103.

Sir,

With reference to your application No. GCT/CT04/FF/2024/46533 dated 22-Nov-2024, please find enclosed herewith the permission in Form CT-06 for conduct of **phase III** clinical trial titled, “**An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone in the Treatment of Pediatric Patients with Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder**” Protocol no. ITI-007-321 India original protocol dated 01 Oct 2024 with a total of up-to 29 subjects from India under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- (i) **India protocol amendment 1 dated 07.02.2025 in compliance to below mentioned conditions of SEC recommendation submitted.**
  - a. **Measures to assess the participants cognitive functions and school performance at baseline and end of treatment.**
  - b. **Instructions to be given to the participants and LAR regarding somnolence and suggesting safety measures.**
- (ii) **Human biological samples i.e. Whole blood, plasma and urine related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO.**
- (iii) **Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;**
- (iv) **where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:**

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:  
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (v) **in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking**

approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

- (vi) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (vii) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (viii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (ix) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (x) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (xi) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (xii) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xiii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiv) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xvi) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xvii) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xviii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xix) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial
- (xx) Merely granting permission to conduct the **clinical trial** with the Investigational Drug Product does not convey or imply that, based on the **clinical trial study data** generated with the investigational drug, permission to market this drug in the country will

automatically be granted to you;

**(xxi)** The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India) &  
Central Licencing Authority  
Stamp

**FORM CT-06**

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR  
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s IQVIA RDS (India) Private Limited, Omega Embassy TechSquare, Marathahalli - Sarjapur Outer Ring Road Kadubeesanahalli Bangalore (India) – 560103** to conduct clinical trial of the new drug or investigational new drug as per **Protocol no. ITI-007-321 India original protocol dated 01 Oct 2024** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date \_\_\_\_\_

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India) &  
Central Licencing Authority  
Stamp

**Note:** The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

**Annexure:**

Details of new drug or investigational new drug:

<b>Names of the new drug or investigational new drug</b>	Lumateperone
<b>Therapeutic class:</b>	Serotonin Dopamine Activity Modulators SDAM
<b>Dosage form:</b>	Capsules
<b>Composition:</b>	Lumateperone Tosylate=42.0000 milligram (mg) In House Specification Active Mannitol =221.0000 milligram(mg) U.S.P.,J.P., Ph.Eur Inactive
<b>Indications:</b>	Treatment of Pediatric Patients with Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder

**Annexure:**

Details of clinical trial site:

<b>Names and address of clinical trial site</b>	<b>Ethics committee details</b>	<b>Name of investigator</b>
GMERS Medical College Gotri, Gotri Road Vadodara Gujarat -390021	Institutional Human Ethics Committee GMERS, Vadodara, Gmers Medical College and Hospital, Gotri Road, Gotri, Vadodara-390021  Ecr/28/Inst/Gj/2013/RR-19	Dr Sandip Hasmukhlal Shah
Magna-Care Ethics committee, Magnum Heart Institute, C/O Chopda Medicare & Research Centre Pvt Ltd., Patil Lane No: 1, Near K.B.H Vidyalaya Canada Corner, Nashik Maharashtra	Magna-care Ethics Committee Chopda Medicare and Research Centre Pvt. Ltd; Magnum Heart Institute, Canada Corner, Nashik, Maharashtra-422005, India  ECR/79/Inst/MH/2013/RR-19	Dr Umesh Suresh Rao Nagapurka
Mysore Medical college and Research Institute and Associate Hospitals, Irwin Road, Mysore Karnataka- 570001	IEC-MMC and RI and Associated Hospital Institutional Ethics Committee-Mysore Medical College & Research Institute and Associated Hospitals, Irwin Road, Mysuru-570001,	Dr Narendra Kumar MS

	Karnataka, India  ECR/134/Inst/KA/2013/RR-19	
Ratandeeep Multispecialty Hospital, Ethics committee, 2nd Floor Nakshatra Complex, Above HDFC Bank, Maninagar Crossroads, Maninagar, Ahmedabad Gujarat -380008	Ratandeeep Institutional Ethics Committee Ratandeeep Multispecialty Hospital, 5thFloor, Nakshatra Complex, Above HDFC Bank, Maninagar Crossroads, Maninagar Ahmedabad, Gujarat-380008 India  ECR/621/Inst/GJ/2014/RR-20	Dr Vaishal Naresh chandra Vora
Vinaya Hospital, Ethics Committee, Vinaya Hospital, P. O. BOX: 717, Karangalpady, Mangalore Karnataka -575003	Ethics Committee Vinaya Hospital and Research Centre, Pintos Lane, Karangalpady Mangaluru, Karnataka-575003 India  ECR/664/Inst/KA/2014/RR-20	Dr Ravisha Thunga Airody
Institutional Belagavi Institute of Medical Sciences, Institutional Ethics committee, Belagavi Institute of Medical Sciences, Dr. B.R. Ambedkar Road, Belagavi Karnataka - 590001	Institutional Ethics Committee BIMS Belagavi Institute of Medical Sciences, Belagavi Dr BR Ambedkar Road Belgaum Belagavi (Belgaum) Karnataka -590001India  ECR/801/Inst/KA/2016/RR-20	Dr Chandrashekar T R
Chethana Centre For Neuropsychiatric Rehabilitation, Providence College Road Malaparamba Kerala -673009	Chethana Centre for Neuropsychiatry Rehabilitation, Providence College Road, Malaparamba, Kozhikode, Kerala, 673009  ECR/1688/Inst/KL/2022	Dr P N Suresh Kumar
Central Institute of Behavioral Sciences, Srividya, 8, Nawab Layout Tilak Nagar Maharashtra -440010	IEC Rughwani Childcare Centre and Hospital Rughwani Childcare Centreand Hospital 22, Sindhu Nagar, Mohanlal Rughwani Marg, Jaripatka, Nagpur Nagpur Maharashtra -	Dr Shailesh Pangaonkar

	440014 India ECR/1444/Inst/MH/2020	
Deva Institute of Healthcare and Research Pvt. Ltd, B27 70MN Durgakund Uttar Pradesh -221005	DMHC Ethics Committee Deva Institute of Health care and Research P. Ltd., B 27/70, MN, Durgakund, Varanasi Uttar Pradesh-221005 India ECR/2/Inst./UP/20213/RR-19	Dr Venu Gopal Jhanwar
Society for Psychiatric Update and Research SPUR, Shanti Nursing Home Kanchanwadi, Paithan Road Chhatrapati Sambhajinagar maharashtra - 431005	ETHICS COMMITTEE, SHANTI NURSING HOME Kanchanwadi, Paithan Road, Chhatrapati Sambhajinagar (Aurangabad) Maharashtra, INDIA Pin -431005 ECR/568/Inst/MH/2014/RR-22	Dr Vinay Barhale
Jawahar Lal Nehru Medical College, Kala Bagh Ajmer Rajasthan -305001	IEC, Jawahar Lal Nehru Medical College Jawahar Lal Nehru Medical College Kala Bagh, Ajmer, Rajasthan-305001, India ECR/1156/Inst/RJ/2018/RR-22	Dr Parth Singh Meena

\*\*\*\*\*